Cell Symposium: Overcoming Therapy Resistance in Cancer

Cell Symposium: Overcoming Therapy Resistance in Cancer

Virtual Event

November 08, 2021 - November 10, 2021

The Cell Symposium: Overcoming Therapy Resistance in Cancer virtual event provides a robust platform for cancer researchers to discuss the mechanisms underlying therapy resistance in cancer, ways to overcome drug resistance, and approaches for personalized medicine. At this event, we showcased our latest 2-D and 3-D patient-derived cancer models, EMT and THP-1 reporter cell lines, human primary cells, cancer panels, immuno-oncology research tools, and more! We also presented a workshop on advanced drug-resistant cell models for cancer therapeutic resistance studies. Explore our resources below to see how we can collaborate on your next project!

Did you miss us at the event and want to speak to one of ATCC’s representatives about a product or service? Contact us so we can discuss your needs.

Read our white papers

Drug Resistance in Cancer: Mechanisms and Models

Learn about the development of drug-resistant cancer models via precise genetic engineering and explore their applications in mechanistic studies and therapeutic screening.

Read the white paper

CRISPR/Cas9-engineered Cancer Models

Learn about the use of CRISPR/Cas9 in engineering cell models that mimic specific cancer genotypes and phenotypes found in clinical tumor samples.

Learn More

Check out our workshop

Advanced Drug-resistant Cell Models for Cancer Therapeutic Resistance Studies

November 10, 2021
10:30 AM – 10:55 AM ET

Fang Tian, PhD, Principal Scientist, Head of Cell Biology R&D group, ATCC

In this workshop, we highlighted how state-of-the-art ATCC drug-resistant cancer cell models created by CRISPR gene editing technology can facilitate the discovery of new types of therapeutics that overcomes drug resistance.

Access the presentation

Human Cancer Models Initiative

ATCC is collaborating with the Human Cancer Models Initiative (HCMI) to offer scientists a wide variety of next-generation 2-D and 3-D patient-derived in vitro cancer models, including organoids.

ATCC is committed to making available a growing collection of models generated by the HCMI, which will include both common as well as rare and understudied examples of cancer from numerous tissues. These HCMI models are valuable tools to study cancer, identify and target novel therapies, and facilitate translational cancer research.

Find next-generation models

Fluorescent blue and green spheres of leukemic cells.

Credible models for immuno-oncology research

Discover now

Resources for cancer research

Gray green and pink bunch of dendric T-cells.

THP-1 reporter cells

ATCC offers luciferase reporters containing the response element of immunologically important transcription factors into the THP-1 cell line. These advanced models provide a robust and highly sensitive means to measure immune activation through in vitro bioluminescence.

Order THP-1 reporter cell lines

Fluorescent red and blue, red, and black colon cells.

EMT reporter cells

Epithelial-mesenchymal transition (EMT) and its reverse, MET, can play critical roles in promoting metastasis and invasion and contribute to drug resistance in carcinoma. ATCC used CRISPR gene editing to develop new reporter lines designed to enable the real-time monitoring of the changing status of cells from epithelial to mesenchymal.

Enhance your research

Next-generation cancer models

ATCC is offering scientists a wide variety of next-generation patient-derived in vitro cancer models, including organoids, which will include both common as well as rare and understudied examples of cancer from numerous tissues. These advanced models are valuable tools to study cancer, identify and target novel therapies, and facilitate translational cancer research.

Discover how

Closeup of a black and red firefly showing his light while standing on a green leaf.

Luciferase-labeled cell lines

ATCC is bridging the gap between the in vitro and the in vivo by offering luciferase-labeled cell lines for biological mechanism studies and drug development; these advanced models provide a relatively simple, robust, and highly sensitive means to measure biological processes and to assess drug efficacy in live animal models through bioluminescence imaging.

Get started

Cancer panels

ATCC offers a wide variety of cancer cell lines for use in research related to cancer genetics, early detection methods, and effective treatment of disease. Panels of these cell lines offer researchers the value of several lines for comprehensive studies. Explore our panels by tissue type, genetic mutation, or molecular signature.

Order cancer panels

Blue DNA strand with sides made of light blue balls.

Isogenic cells

Clinically relevant cell models are critical for studies of molecular and cellular mechanisms of tumors, as well as for drug screening for cancer. With genome editing tools such as CRISPR/Cas9, ATCC has created isogenic cell lines with mutants of key oncogenes, which are ideal for elucidating molecular pathways of cancer progression.

Explore isogenic cells

Explore all cancer resources

Contact us today!

Your ATCC sales representative stands ready to discuss your research needs and provide you with personalized care. Please complete our form to let us know how we can help, and we will start working on your needs right away.

First Name*

Last Name*

Title*

Business Phone

Email Address*

Organization Name*

Select your organization type*

For-profit

Nonprofit

Country*

State or Province

Cell Symposium: Overcoming Therapy Resistance in Cancer inquiry

I agree to receive updates from ATCC and its local distributors.

Yes

We will not share your information outside of our distributors network and solely use it to send relevant communications.

Your form has been successfully submitted